Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 10.78 -0.17 (1.55%)
Day High: 11.07
Day Low:  10.20
Volume:    131,536
4:00 PM ET
02.24.17

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations